Literature DB >> 3281421

Preclinical assessment of abuse liability of drugs.

J L Katz1, S R Goldberg.   

Abstract

Studies that are used in preclinical assessment of the liability of a drug to become an abuse problem are reviewed. These studies examine the capacity of a drug to produce physiological dependence or to function as a reinforcer. Studies that examine physiological dependence by assessing whether a drug reverses signs of withdrawal from a standard drug are rapid, reliable and inexpensive methods for determining if a drug produces dependence of a type similar to the standard. However, these techniques will not determine if the drug produces a unique type of dependence. Studies that examine whether a drug functions as a reinforcer have been predictive of whether a drug will be abused in human populations. Attempts to rank order drugs with respect to their efficacy as reinforcers, however, are not predictive of measures of extent of abuse in human populations. Since abuse of drugs in human populations is a function of societal variables in addition to pharmacological factors, it is unlikely that preclinical assessments will ever yield more than qualitative information on abuse liability of drugs.

Entities:  

Mesh:

Year:  1988        PMID: 3281421     DOI: 10.1007/bf01967174

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  20 in total

1.  Progressive ratio and fixed ratio schedules of cocaine-maintained responding in baboons.

Authors:  R R Griffiths; L D Bradford; J V Brady
Journal:  Psychopharmacology (Berl)       Date:  1979-10       Impact factor: 4.530

2.  Effects of increment size and reinforcer volume on progressive ratio performance.

Authors:  W HODOS; G KALMAN
Journal:  J Exp Anal Behav       Date:  1963-07       Impact factor: 2.468

3.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

4.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Progressive-ratio performance maintained by drug infusions: comparison of cocaine, diethylpropion, chlorphentermine, and fenfluramine.

Authors:  R R Griffiths; J V Brady; J D Snell
Journal:  Psychopharmacology (Berl)       Date:  1978-01-31       Impact factor: 4.530

6.  Clinical and social aspects of marihuana intoxication.

Authors:  A Wikler
Journal:  Arch Gen Psychiatry       Date:  1970-10

7.  Preference in rhesus monkeys given a choice between cocaine and d,l-cathinone.

Authors:  W L Woolverton; C E Johanson
Journal:  J Exp Anal Behav       Date:  1984-01       Impact factor: 2.468

8.  Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys.

Authors:  A M Young; H H Swain; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Comparison of the reinforcing properties of cocaine and procaine in rhesus monkeys.

Authors:  C E Johanson; T Aigner
Journal:  Pharmacol Biochem Behav       Date:  1981-07       Impact factor: 3.533

10.  Opioids: similarity between evaluations of subjective effects and animal self-administration results.

Authors:  R R Griffiths; R L Balster
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

View more
  13 in total

1.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

Review 2.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 3.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

4.  PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission.

Authors:  Giordano de Guglielmo; Miriam Melis; Maria Antonietta De Luca; Marsida Kallupi; Hong Wu Li; Kevin Niswender; Antonio Giordano; Martina Senzacqua; Lorenzo Somaini; Andrea Cippitelli; George Gaitanaris; Gregory Demopulos; Ruslan Damadzic; Jenica Tapocik; Markus Heilig; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2014-09-14       Impact factor: 7.853

5.  Influence of experimental history on nicotine self-administration in squirrel monkeys.

Authors:  Rajeev I Desai; Katherine A Sullivan; Stephen J Kohut; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2016-04-04       Impact factor: 4.530

Review 6.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

7.  The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients.

Authors:  Stephen Bruehl; John W Burns; Steven D Passik; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; Erik Schuster; Daria Orlowska; Christopher R France
Journal:  J Pain       Date:  2015-04-16       Impact factor: 5.820

Review 8.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

Review 9.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

Review 10.  Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data.

Authors:  Gianluigi Tanda; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.